Browsing by Author "Kolay, Murat"

Now showing 1 - 3 of 3

Effects of peroxisome proliferator activated receptor gamma (PPAR gamma) agonist on fasting model applied neuron cultures
(WALTER DE GRUYTER GMBH, 2022-01-01) Pinarbasi, Arzu; Pak, Meltem; Kolay, Murat; Oz Arslan, Devrim; Aksungar, Fehime Benli
Objectives: Peroxisome proliferator activated receptor gamma (PPAR gamma) agonists used for the treatment of Diabetes Mellitus (DM), has important roles on the regulation of metabolism including ketogenesis in fasting and low glucose states. Recently PPAR gamma was proven to have antioxidant and anti-inflammatory effects on neuronal cells. Methods: In the present study, effects of pioglitazone (PPAR gamma agonist) on cell survival, energy metabolism and mitochondrial functions were investigated in glucose deprived fasting model applied SH-SY5Y (ATCC/CRL 2266) cell lines. Before and after pioglitazone treatment
Gestasyonel diyabetli hastalarda ağır metal düzeyleri
(Acıbadem Mehmet Ali Aydınlar Üniversitesi, 2019-01-01) Kolay, Murat; dan. Mustafa Serteser
IGFBP-4: A PROMISING BIOMARKER FOR LUNG CANCER
(SOC MEDICAL BIOCHEMISTS SERBIA, 2021-01-01) Savas, Irem Nur; Ozturk, Akin; Kavas, Murat; Bulut, Ismet; Alparslan, Sumeyye; Eroglu, Selma Aydogan; Baytemir, Cansel Atinkaya; Kolay, Murat; Coskun, Abdurrahman
Background: Insulin-like growth factor binding protein-4 (IGFBP-4), a member of the insulin-like growth factor (IGF) family, transports, and regulates the activity of IGFs. The pregnancy-associated plasma protein-A (PAPP-A) has proteolytic activity towards IGFBP-4, and both proteins have been associated with a variety of cancers, including lung cancer. Thus, we aimed to evaluate the use of IGFBP-4 and PAPP-A as potential biomarkers for lung cancer. Methods: Eighty-three volunteers, including 60 patients with lung cancer and 23 healthy individuals, were included in this study. The patients with lung cancer were selected based on their treatment status, histological subgroup, and stage of the disease. Enzyme-linked immunosorbent assays were used to assess the serum levels of IGFBP-4 and PAPPA, whereas the IGF-1 levels were measured using a chemiluminescent immunometric assay. Results: The serum IGFBP-4 levels in all patient groups, regardless of the treatment status and histological differences, were significantly higher than those in the control group (p < 0.005). However, the serum PAPP-A levels in the untreated patient group were found to be higher than those in the control group, but this difference was not statistically significant (p = 0.086). Conclusions: The serum PAPP-A and IGFBP-4 levels are elevated in lung cancer. However, IGFBP-4 may have better potential than PAPP-A as a lung cancer biomarker.